David T Woodley1, Jon Cogan1, Yingping Hou1, Chao Lyu1, M Peter Marinkovich2,3, Douglas Keene4, Mei Chen1. 1. Department of Dermatology, The Keck School of Medicine, University of Southern California (USC), Los Angeles, California, USA. 2. Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA. 3. Dermatology, Veteran's Affairs Medical Center, Palo Alto, California, USA. 4. Shriners Hospital for Children, Portland, Oregon, USA.
Abstract
BACKGROUND:Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable disease caused by mutations in the gene encoding type VII collagen, the major component of anchoring fibrils (AF). We previously demonstrated that gentamicin produced functional type VII collagen in RDEB cells harboring nonsense mutations. Herein, we determined whether topical or intradermal gentamicin administration induces type VII collagen and AFs in RDEB patients. METHODS: A double-blind, placebo-controlled pilot trial assessed safety and efficacy of topical and intradermal gentamicin in 5 RDEB patients with nonsense mutations. The topical arm tested 0.1% gentamicin ointment or placebo application 3 times daily at 2 open erosion sites for 2 weeks. The intradermal arm tested daily intradermal injection of gentamicin solution (8 mg) or placebo into 2 intact skin sites for 2 days in 4 of 5 patients. Primary outcomes were induction of type VII collagen and AFs at the test sites and safety assessment. A secondary outcome assessed wound closure of topically treated erosions. RESULTS: Both topical and intradermal gentamicin administration induced type VII collagen and AFs at the dermal-epidermal junction of treatment sites. Newly created type VII collagen varied from 20% to 165% of that expressed in normal human skin and persisted for 3 months. Topical gentamicin corrected dermal-epidermal separation, improved wound closure, and reduced blister formation. There were no untoward side effects from gentamicin treatments. Type VII collagen induction did not generate anti-type VII collagen autoantibodies in patients' blood or skin. CONCLUSION:Topical and intradermal gentamicin suppresses nonsense mutations and induces type VII collagen and AFs in RDEB patients. Gentamicin therapy may provide a readily available treatment for RDEB patients with nonsense mutations. TRIAL REGISTRATION: ClinicalTrials.gov NCT02698735. FUNDING: Epidermolysis Bullosa Research Partnership, Epidermolysis Bullosa Medical Research Foundation, NIH, and VA Merit Award.
RCT Entities:
BACKGROUND:Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable disease caused by mutations in the gene encoding type VII collagen, the major component of anchoring fibrils (AF). We previously demonstrated that gentamicin produced functional type VII collagen in RDEB cells harboring nonsense mutations. Herein, we determined whether topical or intradermal gentamicin administration induces type VII collagen and AFs in RDEB patients. METHODS: A double-blind, placebo-controlled pilot trial assessed safety and efficacy of topical and intradermal gentamicin in 5 RDEB patients with nonsense mutations. The topical arm tested 0.1% gentamicin ointment or placebo application 3 times daily at 2 open erosion sites for 2 weeks. The intradermal arm tested daily intradermal injection of gentamicin solution (8 mg) or placebo into 2 intact skin sites for 2 days in 4 of 5 patients. Primary outcomes were induction of type VII collagen and AFs at the test sites and safety assessment. A secondary outcome assessed wound closure of topically treated erosions. RESULTS: Both topical and intradermal gentamicin administration induced type VII collagen and AFs at the dermal-epidermal junction of treatment sites. Newly created type VII collagen varied from 20% to 165% of that expressed in normal human skin and persisted for 3 months. Topical gentamicin corrected dermal-epidermal separation, improved wound closure, and reduced blister formation. There were no untoward side effects from gentamicin treatments. Type VII collagen induction did not generate anti-type VII collagen autoantibodies in patients' blood or skin. CONCLUSION: Topical and intradermal gentamicin suppresses nonsense mutations and induces type VII collagen and AFs in RDEB patients. Gentamicin therapy may provide a readily available treatment for RDEB patients with nonsense mutations. TRIAL REGISTRATION: ClinicalTrials.gov NCT02698735. FUNDING: Epidermolysis Bullosa Research Partnership, Epidermolysis Bullosa Medical Research Foundation, NIH, and VA Merit Award.
Authors: Jon Cogan; Jacqueline Weinstein; Xinyi Wang; Yingping Hou; Sabrina Martin; Andrew P South; David T Woodley; Mei Chen Journal: Mol Ther Date: 2014-07-23 Impact factor: 11.454
Authors: Johannes S Kern; Stefan Loeckermann; Anja Fritsch; Ingrid Hausser; Wera Roth; Thomas M Magin; Claudia Mack; Marcel L Müller; Oliver Paul; Patrick Ruther; Leena Bruckner-Tuderman Journal: Mol Ther Date: 2009-06-30 Impact factor: 11.454
Authors: John E Wagner; Akemi Ishida-Yamamoto; John A McGrath; Maria Hordinsky; Douglas R Keene; David T Woodley; Mei Chen; Megan J Riddle; Mark J Osborn; Troy Lund; Michelle Dolan; Bruce R Blazar; Jakub Tolar Journal: N Engl J Med Date: 2010-08-12 Impact factor: 91.245
Authors: Tracy Wong; Luke Gammon; Lu Liu; Jemima E Mellerio; Patricia J C Dopping-Hepenstal; John Pacy; George Elia; Rosemary Jeffery; Irene M Leigh; Harshad Navsaria; John A McGrath Journal: J Invest Dermatol Date: 2008-04-03 Impact factor: 8.551
Authors: J C Lapiere; D T Woodley; M G Parente; T Iwasaki; K C Wynn; A M Christiano; J Uitto Journal: J Clin Invest Date: 1993-10 Impact factor: 14.808
Authors: David T Woodley; Gerald G Krueger; Cynthia M Jorgensen; Janet A Fairley; Tom Atha; Yi Huang; Lawrence Chan; Douglas R Keene; Mei Chen Journal: J Invest Dermatol Date: 2003-11 Impact factor: 8.551
Authors: Isabelle Sermet-Gaudelus; Michel Renouil; Anne Fajac; Laure Bidou; Bastien Parbaille; Sébastien Pierrot; Nolwen Davy; Elise Bismuth; Philippe Reinert; Gérard Lenoir; Jean François Lesure; Jean Pierre Rousset; Aleksander Edelman Journal: BMC Med Date: 2007-03-29 Impact factor: 8.775
Authors: Su M Lwin; Farhatullah Syed; Wei-Li Di; Tendai Kadiyirire; Lu Liu; Alyson Guy; Anastasia Petrova; Alya Abdul-Wahab; Fiona Reid; Rachel Phillips; Maria Elstad; Christos Georgiadis; Sophia Aristodemou; Patricia A Lovell; James R McMillan; John Mee; Snaigune Miskinyte; Matthias Titeux; Linda Ozoemena; Rashida Pramanik; Sonia Serrano; Racheal Rowles; Clarisse Maurin; Elizabeth Orrin; Magdalena Martinez-Queipo; Ellie Rashidghamat; Christos Tziotzios; Alexandros Onoufriadis; Mei Chen; Lucas Chan; Farzin Farzaneh; Marcela Del Rio; Jakub Tolar; Johann W Bauer; Fernando Larcher; Michael N Antoniou; Alain Hovnanian; Adrian J Thrasher; Jemima E Mellerio; Waseem Qasim; John A McGrath Journal: JCI Insight Date: 2019-06-06
Authors: Vadim Lincoln; Jon Cogan; Yingping Hou; Michaela Hirsch; Michelle Hao; Vitali Alexeev; Michele De Luca; Laura De Rosa; Johann W Bauer; David T Woodley; Mei Chen Journal: Proc Natl Acad Sci U S A Date: 2018-06-26 Impact factor: 11.205
Authors: I I Ryumina; K V Goryunov; D N Silachev; Yu A Shevtsova; V A Babenko; N M Marycheva; Yu Yu Kotalevskaya; V V Zubkov; G T Zubkov Journal: Bull Exp Biol Med Date: 2021-05-29 Impact factor: 0.804